Igc Pharma Inc (IGC)

$0.42 +0.00 (1.13%)
Market Cap 39.38M
Revenue (ttm) 1.27M
Net Income (ttm) -7.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -560.63%
Debt to Equity Ratio 0.02
Volume 400,200
Avg Vol 3,682,302
Day's Range N/A - N/A
Shares Out 90.81M
Stochastic %K 29%
Beta 1.08
Analysts Sell
Price Target $4.00

Company Profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatment of metabolic disorders and Alzheimer's disease; and IGC-1A to treat metabolic disorders. The comp...

Industry: Biotechnology
Sector: Healthcare
Phone: (301) 983-0998
Address:
10224 Falls Road, Potomac, United States
oii
oii Sep. 10 at 10:03 AM
$IGC we are still good
0 · Reply
CarlSpagler
CarlSpagler Sep. 9 at 4:51 PM
$IGC who is ready ?
1 · Reply
Tom678
Tom678 Sep. 9 at 2:19 PM
$IGC huge news
0 · Reply
topstockalerts
topstockalerts Sep. 9 at 1:56 PM
$IGC Another one paying off 💪
0 · Reply
DARKP00L
DARKP00L Sep. 9 at 10:32 AM
$IGC 05:50 on Sep. 09 2025 Cannabis Based Pain Relief Solution Receives European Patent Approval #tradeideas
0 · Reply
MK10
MK10 Sep. 8 at 8:13 PM
$IGC I missed buying this one today by .001 cents! lol Maybe I'll get it tomorrow:)
0 · Reply
TRIPPIEREDD
TRIPPIEREDD Sep. 8 at 2:54 PM
$IGC buy more now if you can
0 · Reply
CarlSpagler
CarlSpagler Sep. 8 at 2:34 PM
$IGC gifts 🎁
0 · Reply
Tom678
Tom678 Sep. 8 at 9:13 AM
$IGC $1 very soon
1 · Reply
oii
oii Sep. 8 at 8:17 AM
$IGC lets go, green week ahead
0 · Reply
Latest News on IGC
IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

Sep 9, 2025, 9:00 AM EDT - 1 day ago

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

Sep 2, 2025, 9:00 AM EDT - 8 days ago

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

Aug 28, 2025, 9:00 AM EDT - 13 days ago

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

Aug 27, 2025, 9:00 AM EDT - 14 days ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

Aug 25, 2025, 9:00 AM EDT - 16 days ago

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

Aug 19, 2025, 9:00 AM EDT - 22 days ago

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

Aug 12, 2025, 9:00 AM EDT - 4 weeks ago

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

Aug 5, 2025, 9:00 AM EDT - 5 weeks ago

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

Jul 23, 2025, 9:00 AM EDT - 7 weeks ago

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

Jul 21, 2025, 9:00 AM EDT - 7 weeks ago

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

Jul 10, 2025, 3:10 PM EDT - 2 months ago

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

Jun 30, 2025, 9:00 AM EDT - 2 months ago

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

Jun 27, 2025, 8:30 AM EDT - 2 months ago

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

Jun 23, 2025, 8:30 AM EDT - 2 months ago

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

May 22, 2025, 9:30 AM EDT - 3 months ago

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

May 12, 2025, 9:30 AM EDT - 4 months ago

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

IGC Pharma Welcomes Strategic Investment from Advisors

Apr 24, 2025, 9:30 AM EDT - 4 months ago

IGC Pharma Welcomes Strategic Investment from Advisors

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

Apr 21, 2025, 9:30 AM EDT - 5 months ago

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

Apr 8, 2025, 9:30 AM EDT - 5 months ago

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

Apr 1, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

Mar 26, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

Mar 20, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

Mar 17, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.

Mar 12, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"

Mar 10, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

Mar 4, 2025, 9:00 AM EST - 6 months ago

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

Feb 20, 2025, 9:00 AM EST - 7 months ago

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

IGC Pharma Reports Third Quarter Fiscal 2025 Results

Feb 18, 2025, 8:30 AM EST - 7 months ago

IGC Pharma Reports Third Quarter Fiscal 2025 Results

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

Feb 11, 2025, 8:30 AM EST - 7 months ago

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

Jan 28, 2025, 8:30 AM EST - 8 months ago

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

Jan 13, 2025, 8:30 AM EST - 8 months ago

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

Jan 8, 2025, 8:30 AM EST - 8 months ago

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025

Dec 19, 2024, 7:00 PM EST - 9 months ago

IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025

IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology

Dec 2, 2024, 8:30 AM EST - 10 months ago

IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

Nov 25, 2024, 8:30 AM EST - 10 months ago

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline

Nov 14, 2024, 8:30 AM EST - 10 months ago

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies

Nov 6, 2024, 8:30 AM EST - 10 months ago

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

Oct 17, 2024, 8:30 AM EDT - 11 months ago

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge

Oct 3, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment

Sep 18, 2024, 8:00 AM EDT - 1 year ago

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease

Sep 4, 2024, 8:00 AM EDT - 1 year ago

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

Aug 22, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

IGC Pharma Reports First Quarter Fiscal 2025 Results

Aug 8, 2024, 9:30 PM EDT - 1 year ago

IGC Pharma Reports First Quarter Fiscal 2025 Results

IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target

Jul 18, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target

Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

Jul 9, 2024, 9:10 AM EDT - 1 year ago

Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease

Jun 25, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease

IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol

Jun 10, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol

IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1

May 28, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1

IGC Pharma to Attend BIO International Convention 2024

May 21, 2024, 2:00 PM EDT - 1 year ago

IGC Pharma to Attend BIO International Convention 2024

IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two

Apr 16, 2024, 7:00 AM EDT - 1 year ago

IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two

oii
oii Sep. 10 at 10:03 AM
$IGC we are still good
0 · Reply
CarlSpagler
CarlSpagler Sep. 9 at 4:51 PM
$IGC who is ready ?
1 · Reply
Tom678
Tom678 Sep. 9 at 2:19 PM
$IGC huge news
0 · Reply
topstockalerts
topstockalerts Sep. 9 at 1:56 PM
$IGC Another one paying off 💪
0 · Reply
DARKP00L
DARKP00L Sep. 9 at 10:32 AM
$IGC 05:50 on Sep. 09 2025 Cannabis Based Pain Relief Solution Receives European Patent Approval #tradeideas
0 · Reply
MK10
MK10 Sep. 8 at 8:13 PM
$IGC I missed buying this one today by .001 cents! lol Maybe I'll get it tomorrow:)
0 · Reply
TRIPPIEREDD
TRIPPIEREDD Sep. 8 at 2:54 PM
$IGC buy more now if you can
0 · Reply
CarlSpagler
CarlSpagler Sep. 8 at 2:34 PM
$IGC gifts 🎁
0 · Reply
Tom678
Tom678 Sep. 8 at 9:13 AM
$IGC $1 very soon
1 · Reply
oii
oii Sep. 8 at 8:17 AM
$IGC lets go, green week ahead
0 · Reply
magaly
magaly Sep. 7 at 2:08 AM
$IGC has a solid upward trend.
0 · Reply
gratoserrano
gratoserrano Sep. 6 at 6:04 PM
$IGC The IGC numbers are good.
0 · Reply
super35362
super35362 Sep. 6 at 4:48 PM
$IGC We have over 30,000 watchers. Who is holding, and what is the average ?
3 · Reply
CarlSpagler
CarlSpagler Sep. 6 at 12:22 AM
$IGC it’s getting close. I’m adding more next week
0 · Reply
gratoserrano
gratoserrano Sep. 5 at 7:44 PM
$IGC I opened a small position here; I can see that it has upside potential.
0 · Reply
TRIPPIEREDD
TRIPPIEREDD Sep. 5 at 5:39 PM
$IGC Friday green???
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Sep. 5 at 12:46 PM
$IGC
0 · Reply
krishkk
krishkk Sep. 5 at 12:10 PM
$IGC when is the pump.?
0 · Reply
angel6
angel6 Sep. 4 at 3:25 PM
$IGC it hasn’t done anything for more then a year Just trials this ,trials that. Keep everyone trailing along
0 · Reply
super35362
super35362 Sep. 4 at 2:31 PM
$IGC
0 · Reply
TRIPPIEREDD
TRIPPIEREDD Sep. 4 at 2:21 PM
$IGC been holding since .40
0 · Reply
oii
oii Sep. 4 at 4:25 AM
$IGC 0,50 this week would be awesome
0 · Reply